• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Hyperimmune immunoglobulin does not improve outcomes in patients hospitalized with COVID-19

byJessie WillisandTeddy Guo
February 16, 2022
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Hyperimmune intravenous immunoglobulin (hIVIG) did not increase odds of better outcomes in patients with COVID-19 compared to placebo.

2. The most common adverse reactions with hIVIG were infusion reactions and there were significantly more grade 3 or higher adverse reactions in the hIVIG group compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Passive immunization generally involves the administration of antibodies to provide temporary, but rapid immune response to an acute infection. Hyperimmune intravenous immunoglobulins (hIVIG) are purified immunoglobulin G derived from patients who have recovered from COVID-19 infection. To date, there is limited evidence regarding their effectiveness in patients hospitalized with COVID-19. The aim of this randomized controlled trial was to evaluate the safety and efficacy of hIVIG in hospitalized patients with COVID-19. When added to the current standard treatment regimen, hIVIG was not seen to improve outcomes compared with placebo in patients with COVID-19. Adverse reactions, mainly infusion reactions, were significantly more common in patients in the hIVIG group. Limitations of this study include the delayed time to treatment, which was a median of 8 days from symptom onset. Nonetheless, there may still be a role for future studies in different patient populations.

Click to read the study in The Lancet.

Relevant Reading: Antibody responses to SARS-CoV-2 in patients with COVID-19

In-Depth [randomized controlled trial]: This study was a double-blind, placebo-controlled, phase 3 clinical trial evaluating the efficacy of anti-SARS-CoV-2 hIVIG. The study enrolled 593 patients hospitalized with COVID-19 aged 18 years and older. The average age of participants was 59 years and 43% were female. Patients were randomized (1:1) to receive hIVIG (400 mg/kg) or placebo. All patients received the standard of care, including remdesivir. The primary outcome was clinical status on day 7 post-infusion and patients were followed up to 28 days from randomization. The median time from symptom onset to randomization was 8 days.

RELATED REPORTS

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

2 Minute Medicine Rewind January 23, 2023

Unvaccinated status increases risk of long COVID symptoms

For the primary outcome, the odds ratio for a more favorable clinical outcome on day 7 for the hIVIG group was 1.06 (95% CI 0.77-1.45, p=0.72). Rates of hospitalization and death were not significantly different between groups. The most common adverse reaction was infusion reactions in the hIVIG group. 6% of patients in the hIVIG group compared with 1% of the placebo group reported grade 3 or higher infusion reactions (p=0.012).

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: convalescent plasmaCOVID-19hyperimmune intravenous immunoglobulinintravenous immunoglobulinpassive immunitypassive immunizationSARS-CoV-2
Previous Post

Pregnant patients with epilepsy may benefit from increased doses of anticonvulsant medications

Next Post

#VisualAbstract: Mobile stroke units associated with better outcomes for acute ischemic stroke management

RelatedReports

Social networks play key roles in parental vaccination decisions
Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

January 30, 2023
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 30, 2023
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
School nurses essential in design and implementation of school safety programs
Chronic Disease

Combined visual-olfactory training for COVID-19 resultant olfactory loss

January 23, 2023
Next Post
#VisualAbstract: Mobile stroke units associated with better outcomes for acute ischemic stroke management

#VisualAbstract: Mobile stroke units associated with better outcomes for acute ischemic stroke management

Provision of medically-tailored meals linked with lower admissions and medical spending

Wellness Check: Nutrition

#VisualAbstract: Individualized dosing of anti-thymocyte globulin may improves outcomes of allogeneic haematopoietic stem-cell transplantation in children

#VisualAbstract: Individualized dosing of anti-thymocyte globulin may improves outcomes of allogeneic haematopoietic stem-cell transplantation in children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options